Examine individual changes

'{{RiskData | risk_name = Vaginal and Sexual Symptoms During Perimenopause and Menopause | risk_summary = Risk of vaginal dryness, painful intercourse (dyspareunia), and other symptoms of Genitourinary Syndrome of Menopause (GSM) due to declining estrogen levels. | baseline_risk_prevalence = 40-60 | baseline_dyspareunia_prevalence = 40 | local_hrt_symptom_resolution_low = 50 | local_hrt_symptom_resolution_high = 70 | systemic_hrt_symptom_resolution = 90 | systemic_hrt_needs_local = 10 }} &lt;riskdata table=&quot;SystemicHRT_Risk&quot; columns=&quot;Risk Factor|Breast_Cancer_Cases|Blood_Clot_Cases&quot;&gt; Breast Cancer|4|0 Blood Clots|0|8 &lt;/riskdata&gt; &lt;p&gt;This table quantifies the increased absolute risk associated with systemic combined hormone replacement therapy (HRT) over a 5-year period for women who start therapy within 10 years of menopause. The values represent additional cases per 1,000 women over this timeframe. The breast cancer risk is based on the combined estrogen-progestin arm of the Women&#39;s Health Initiative study. The blood clot risk is based on oral HRT and is per 10,000 women per year.&lt;/p&gt; * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3872828/ The Women's Health Initiative Randomized Controlled Trial and Progestin Therapy] * [https://www.ncbi.nlm.nih.gov/books/NBK430910/ Hormone Therapy and Menopause: An Overview] &lt;riskdata table=&quot;SymptomSeverity_Mitigation&quot; columns=&quot;Mitigation Strategy|Symptom Improvement (%)&quot;&gt; Local HRT|80 Systemic HRT|90 Non-Hormonal Lubricants/Moisturizers|50 &lt;/riskdata&gt; &lt;p&gt;This table shows the approximate percentage of women who report significant improvement in genitourinary symptoms of menopause (GSM) based on different mitigation strategies. These values are drawn from systematic reviews and patient satisfaction surveys and represent a general range of efficacy.&lt;/p&gt; * [https://www.menopause.org/docs/default-source/2013/menopause-and-vaginal-dryness.pdf The North American Menopause Society - Menopause and Vaginal Dryness] * [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6400511/ Efficacy and safety of vaginal estrogen therapy for genitourinary syndrome of menopause] &lt;riskmodel name=&quot;GSM_Risk&quot;&gt; The risk of developing moderate to severe vaginal and sexual symptoms without treatment is between **{{#expr: {baseline_risk_prevalence} / 100 }}** and **{{#expr: 84 / 100 }}**. This is equivalent to **{{#expr: {baseline_risk_prevalence} / 100 * 100 }}%** to **84%** of postmenopausal women. {{\#if: {{{MitigationStrategy|}}} | <br> '''Risk with Mitigation:''' When using {{{MitigationStrategy}}}, the likelihood of significant symptom improvement is **{{\#expr: {{Symptom Improvement (%)}} / 100 }}**, or a **{{Symptom Improvement (%)}}%** chance of success. <br> {{\#if: {{\#ifexpr: {{SystemicHRT\_Risk|row=Breast Cancer|col=Breast\_Cancer\_Cases}} \> 0 }} | '''Associated Risks:''' For every 1,000 women who use systemic HRT for 5 years, there are approximately **{{SystemicHRT\_Risk|row=Breast Cancer|col=Breast\_Cancer\_Cases}}** additional cases of breast cancer. The risk of a blood clot is **{{\#expr: {{SystemicHRT\_Risk|row=Blood Clots|col=Blood\_Clot\_Cases}} / 10000 }}**, or about **{{SystemicHRT\_Risk|row=Blood Clots|col=Blood\_Clot\_Cases}}** additional cases per 10,000 women per year with oral HRT. | <br> '''Associated Risks:''' Local HRT has a very low risk profile with minimal systemic absorption. }} }} &lt;/riskmodel&gt; &lt;p&gt;The calculation for the baseline risk is a direct expression of the provided prevalence range. The mitigation risk is calculated as a simple percentage based on user selection.&lt;/p&gt; Data and risk models are used on the [[Risk\_of\_Vaginal\_Symptoms\_Without\_HRT|main page]]. Initially created by Gemini (Google).'